|
STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pierre Fabre; Roche/Genentech; SERVIER; Ventana Medical Systems |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Pierre Fabre; Seagen; Servier; SERVIER; Tesaro; Transgene |
Travel, Accommodations, Expenses - MSD Oncology |
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; Gercor |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - SERVIER |
Speakers' Bureau - SERVIER |
Expert Testimony - SERVIER |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Hospira |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Merck; MSD Oncology; Roche |
Travel, Accommodations, Expenses - Merck; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; MSD; Roche; Sanofi |
Consulting or Advisory Role - Bayer |
|
Travel, Accommodations, Expenses - Bayer; MSD; Roche |
|
Marie-Line Garcia-Larnicol |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Medison; MSD |
Travel, Accommodations, Expenses - Merck Serono |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Roche; SERVIER; Takeda |
Speakers' Bureau - Biomnis Ireland |
Research Funding - Roche Ireland (Inst) |
|
|
|
Research Funding - AstraZeneca/MedImmune (Inst) |
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech |
|
|
No Relationships to Disclose |